journal article·2022-05-25

Adenoviral Vector for Enhanced Prostate Cancer Specific Transferrin Conjugated Drug Targeted Therapy

Jing Peng, Kangkang Liu, Lin Cao, Dengyi Duan, Guodong Song, Shuang Liu, Lining Wang, Jianmin Li, Xuening Zhang, Kai Huang, Yang Zhao, Yuanjie Niu, Gang Han

Nano Letters· Volume 22· Issue 10
Publisher page

Abstract

Prostate cancer (PCa) is one of the leading causes of death for men worldwide. Unlike some other types of cancer, there is a lack of targeted therapy for prostate cancer patients that can kill cancer cells but do much less damage to the normal tissue. In this paper, we report on an adenoviral vector enhanced prostate cancer specific transferrin conjugated drug targeted therapy. In particular, a functional PCa-specific gene probe is introduced to drive and up-regulate the transferrin receptor expression on the PCa via adenoviral vector. As a result, significantly enhanced accumulation of nanoscale transferrin-doxorubicin (Tf-DOX) protein drug conjugates and concomitant notably elevated PCa tumor inhibition are observed. This conceptual strategy provides the proof-of-concept for the targeted therapy of PCa that is highly desired but not yet developed.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Prostate Cancer Treatment and Research · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China

Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, 364 Plantation Street, LRB 806, Worcester, Massachusetts 01605, United States

Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China

Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China

Department of Gastroenterology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China

Funding

Natural Science Foundation of Tianjin City · University of Massachusetts · National Natural Science Foundation of China · Tianjin Municipal Education Commission

References (28)

Show source-provided references
1. 10.3322/caac.2159010.3322/caac.21590 ↗
2. 10.1056/NEJMcp110364210.1056/NEJMcp1103642 ↗
3. 10.1016/S0140-6736(21)00950-810.1016/S0140-6736(21)00950-8 ↗
4. 10.1056/NEJMoa04131810.1056/NEJMoa041318 ↗
5. 10.1038/nrurol.2013.18510.1038/nrurol.2013.185 ↗
6. 10.1038/nrclinonc.2014.6810.1038/nrclinonc.2014.68 ↗
7. 10.1016/j.ejpb.2015.03.01810.1016/j.ejpb.2015.03.018 ↗
8. 10.1002/med.2175010.1002/med.21750 ↗
9. 10.1016/j.euf.2021.06.00610.1016/j.euf.2021.06.006 ↗
10. 10.2174/138161282266616102616234710.2174/1381612822666161026162347 ↗
11. 10.1021/acs.nanolett.7b0082810.1021/acs.nanolett.7b00828 ↗
12. 10.1002/med.1000810.1002/med.10008 ↗
13. 10.1023/A:102624650078810.1023/A:1026246500788 ↗
14. 10.1038/nm1297-136210.1038/nm1297-1362 ↗
15. 10.1021/js970246a10.1021/js970246a ↗
16. 10.1021/acsami.7b1516510.1021/acsami.7b15165 ↗
17. 10.1016/j.cbi.2014.06.01310.1016/j.cbi.2014.06.013 ↗
18. 10.1016/j.eururo.2018.03.02810.1016/j.eururo.2018.03.028 ↗
19. 10.1016/j.eururo.2017.10.03610.1016/j.eururo.2017.10.036 ↗
20. 10.1038/s41585-020-00400-w10.1038/s41585-020-00400-w ↗
21. 10.1093/jnci/87.1.4110.1093/jnci/87.1.41 ↗
22. 10.1002/adma.20190092810.1002/adma.201900928 ↗
23. de Kok J. B. · Cancer Research · 2002 · 62 · 2695
24. 10.1093/jnci/85.5.39410.1093/jnci/85.5.394 ↗
25. 10.1158/1535-7163.MCT-05-026610.1158/1535-7163.MCT-05-0266 ↗
26. 10.1038/s41591-018-0184-610.1038/s41591-018-0184-6 ↗
27. 10.2174/15665231179615036310.2174/156652311796150363 ↗
28. 10.1200/JCO.2017.75.821910.1200/JCO.2017.75.8219 ↗